BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/15/2018 12:09:30 PM | Browse: 1059 | Download: 1643
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 40971
Country South Korea
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Editorial
Article Title Inhibiting focal adhesion kinase: A potential target for enhancing therapeutic efficacy in colorectal cancer therapy
Manuscript Source Invited Manuscript
All Author List Keun-Yeong Jeong
ORCID
Author(s) ORCID Number
Keun-Yeong Jeong http://orcid.org/0000-0002-4933-3493
Funding Agency and Grant Number
Corresponding Author Keun-Yeong Jeong, PhD, Division of Research and Development, Metimedi Pharmaceuticals, R and D Division, Metimedi Pharmaceuticals Co., 263, Central-ro, Yeonsu-Gu, Incheon 22006, South Korea. alvirus@naver.com
Key Words Colorectal cancer; Focal adhesion kinase; Focal adhesion kinase inhibitor; Anticancer effect
Core Tip Despite ongoing development in treatment for colorectal cancer (CRC), effective markers for treatment of CRC have not been elucidated. FAK association with various kinases for progression and invasion of CRC has re­cently gained attention. The possibility for this associa­tion is accounted that FAK is interactions with integrins, growth factor receptors, and adjacent kinase domain. Targeting FAK is possible to explain the mechanism at the upstream level by which can mediate the expres­sion of various survival signaling and inhibition of onco-suppressor genes as well as inducing migration and invasion of the CRC cells. Therefore, FAK could be a pro­gnostic marker and a potential candidate target for CRC therapies.
Publish Date 2018-10-15 12:09
Citation Jeong KY. Inhibiting focal adhesion kinase: A potential target for enhancing therapeutic efficacy in colorectal cancer therapy. World J Gastrointest Oncol 2018; 10(10): 290-292
URL http://www.wjgnet.com/1948-5204/full/v10/i10/290.htm
DOI http://dx.doi.org/10.4251/wjgo.v10.i10.290
Full Article (PDF) WJGO-10-290.pdf
Full Article (Word) WJGO-10-290.doc